Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia.

Schmidt RE, Feng D, Wang Q, Green KG, Snipes LL, Yamin M, Brines M

Experimental neurology18 Aug 2011Cited by 26 (Europe PMC)

PMID21872588PMCIDPMC3202026DOI10.1016/j.expneurol.2011.05.025PepBankPUB-21872588

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In diabetic Akita mice, 7 weeks of ARA290 did not change blood glucose.
In plain wordsIn diabetic mice, ARA290 did not change blood sugar.
Peptide
Cibinetide (ARA-290)
Outcome
No significant changeBlood glucose
Study
Mousen: not reported in source
Akita (Ins2 Akita) diabetic mouse
Comparator
Untreated diabetic mice
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 7 weeksAs given in this study (Mouse).
Source sentences
Summary
Treatment with ARA290 for 7 weeks beginning at 4 months of diabetes did not result in altered metabolic severity of diabetes as measured by blood glucose, body weight or HbA1c levels.
1 context sentence(design, population, supporting numbers)
Summary · context
We have examined the effect of insulin implants resulting in normoglycemia and injections of ARA290, a small erythropoietin peptide which has no effect on glycemic parameters, on the reversal of established neuritic dystrophy and neuronopathy.
Report a problemFND-2187258801
02AnimalAnimal study (in vivo)Efficacy outcome
In diabetic Akita mice, 7 weeks of ARA290 did not change body weight.
In plain wordsIn diabetic mice, ARA290 did not change body weight.
Peptide
Cibinetide (ARA-290)
Outcome
No significant changeBody weight
Study
Mousen: not reported in source
Akita (Ins2 Akita) diabetic mouse
Comparator
Untreated diabetic mice
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 7 weeksAs given in this study (Mouse).
Source sentences
Summary
Treatment with ARA290 for 7 weeks beginning at 4 months of diabetes did not result in altered metabolic severity of diabetes as measured by blood glucose, body weight or HbA1c levels.
1 context sentence(design, population, supporting numbers)
Summary · context
We have examined the effect of insulin implants resulting in normoglycemia and injections of ARA290, a small erythropoietin peptide which has no effect on glycemic parameters, on the reversal of established neuritic dystrophy and neuronopathy.
Report a problemFND-2187258802
03AnimalAnimal study (in vivo)Efficacy outcome
In diabetic Akita mice, 7 weeks of ARA290 did not change HbA1c levels.
In plain wordsIn diabetic mice, ARA290 did not change HbA1c, a long-term blood sugar marker.
Peptide
Cibinetide (ARA-290)
Outcome
No significant changeHbA1c
Study
Mousen: not reported in source
Akita (Ins2 Akita) diabetic mouse
Comparator
Untreated diabetic mice
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 7 weeksAs given in this study (Mouse).
Source sentences
Summary
Treatment with ARA290 for 7 weeks beginning at 4 months of diabetes did not result in altered metabolic severity of diabetes as measured by blood glucose, body weight or HbA1c levels.
1 context sentence(design, population, supporting numbers)
Summary · context
We have examined the effect of insulin implants resulting in normoglycemia and injections of ARA290, a small erythropoietin peptide which has no effect on glycemic parameters, on the reversal of established neuritic dystrophy and neuronopathy.
Report a problemFND-2187258803
04AnimalAnimal study (in vivo)Efficacy outcome
In diabetic Akita mice, ARA290 decreased neuritic dystrophy by 55-74% compared with untreated diabetics or a 4-month treatment-onset group.
In plain wordsIn diabetic mice, ARA290 reduced nerve-ending damage in sympathetic ganglia compared with untreated diabetic mice.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseNeuritic dystrophy in sympathetic ganglia
Study
Mousen: not reported in source
Akita (Ins2 Akita) diabetic mouse
Comparator
Untreated diabetic mice
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · 7 weeksAs given in this study (Mouse).
Measurements
Decrease in neuritic dystrophy
55 to 74%
ARA290 vs untreated diabetics
Source sentences
Summary
ARA290 treatment was able to decrease neuritic dystrophy by 55-74% compared to untreated diabetics or in comparison to a separate group of diabetic animals representing the 4 month treatment onset point.
1 context sentence(design, population, supporting numbers)
Summary · context
We have examined the effect of insulin implants resulting in normoglycemia and injections of ARA290, a small erythropoietin peptide which has no effect on glycemic parameters, on the reversal of established neuritic dystrophy and neuronopathy.
Report a problemFND-2187258804
05AnimalAnimal study (in vivo)Efficacy outcome
In diabetic Akita mice, ARA290 had no effect on ganglionic neuron number.
In plain wordsIn diabetic mice, ARA290 did not change the number of nerve cells in the ganglia.
Peptide
Cibinetide (ARA-290)
Outcome
No significant changeGanglionic neuron number
Study
Mousen: not reported in source
Akita (Ins2 Akita) diabetic mouse
Comparator
Untreated diabetic mice
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · 7 weeksAs given in this study (Mouse).
Source sentences
Summary
Surprisingly, there was no effect of ARA290 on ganglionic neuron number or ongoing neuronopathy (pale/degenerating neurons) in diabetic Akita mice during this time period.
1 context sentence(design, population, supporting numbers)
Summary · context
We have examined the effect of insulin implants resulting in normoglycemia and injections of ARA290, a small erythropoietin peptide which has no effect on glycemic parameters, on the reversal of established neuritic dystrophy and neuronopathy.
Report a problemFND-2187258805
06AnimalAnimal study (in vivo)Efficacy outcome
In diabetic Akita mice, ARA290 had no effect on ongoing neuronopathy.
In plain wordsIn diabetic mice, ARA290 did not change the number of degenerating nerve cells.
Peptide
Cibinetide (ARA-290)
Outcome
No significant changeOngoing neuronopathy (pale or degenerating neurons)
Study
Mousen: not reported in source
Akita (Ins2 Akita) diabetic mouse
Comparator
Untreated diabetic mice
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · 7 weeksAs given in this study (Mouse).
Source sentences
Summary
Surprisingly, there was no effect of ARA290 on ganglionic neuron number or ongoing neuronopathy (pale/degenerating neurons) in diabetic Akita mice during this time period.
1 context sentence(design, population, supporting numbers)
Summary · context
We have examined the effect of insulin implants resulting in normoglycemia and injections of ARA290, a small erythropoietin peptide which has no effect on glycemic parameters, on the reversal of established neuritic dystrophy and neuronopathy.
Report a problemFND-2187258806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.